Kim Joseph Y, Balamurugan Arumugam, Azari Kodi, Hofmann Christian, Ng Hwee L, Reed Elaine F, McDiarmid Suzanne, Yang Otto O
Division of Infectious Diseases, Department of Medicine, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America; Department of Microbiology, Immunology, and Molecular Genetics, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Division of Infectious Diseases, Department of Medicine, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
PLoS One. 2015 Aug 19;10(8):e0136235. doi: 10.1371/journal.pone.0136235. eCollection 2015.
Immune prophylaxis and treatment of transplanted tissue rejection act indiscriminately, risking serious infections and malignancies. Although animal data suggest that cellular immune responses causing rejection may be rather narrow and predictable based on genetic background, there are only limited data regarding the clonal breadth of anti-donor responses in humans after allogeneic organ transplantation. We evaluated the graft-infiltrating CD8+ T lymphocytes in skin punch biopsies of a transplanted hand over 178 days. Profiling of T cell receptor (TCR) variable gene usage and size distribution of the infiltrating cells revealed marked skewing of the TCR repertoire indicating oligoclonality, but relatively normal distributions in the blood. Although sampling limitation prevented complete assessment of the TCR repertoire, sequencing further identified 11 TCR clonal expansions that persisted through varying degrees of clinical rejection and immunosuppressive therapy. These 11 clones were limited to three TCR beta chain variable (BV) gene families. Overall, these data indicate significant oligoclonality and likely restricted BV gene usage of alloreactive CD8+ T lymphocytes, and suggest that changes in rejection status are more due to varying regulation of their activity or number rather than shifts in the clonal populations in the transplanted organ. Given that controlled animal models produce predictable BV usage in T lymphocytes mediating rejection, understanding the determinants of TCR gene usage associated with rejection in humans may have application in specifically targeted immunotherapy.
移植组织排斥反应的免疫预防和治疗具有非特异性,存在引发严重感染和恶性肿瘤的风险。尽管动物实验数据表明,基于遗传背景,引发排斥反应的细胞免疫反应可能较为局限且具有可预测性,但关于同种异体器官移植后人类抗供体反应的克隆广度的数据仍然有限。我们在178天内对一例移植手的皮肤穿刺活检组织中的移植物浸润CD8 + T淋巴细胞进行了评估。对T细胞受体(TCR)可变基因的使用情况以及浸润细胞的大小分布进行分析,结果显示TCR库存在明显的偏态分布,表明存在寡克隆性,但血液中的分布相对正常。尽管由于样本限制无法对TCR库进行全面评估,但测序进一步鉴定出11个TCR克隆扩增,这些克隆在不同程度的临床排斥反应和免疫抑制治疗过程中持续存在。这11个克隆仅限于三个TCRβ链可变(BV)基因家族。总体而言,这些数据表明同种异体反应性CD8 + T淋巴细胞存在显著的寡克隆性,且BV基因的使用可能受到限制,这表明排斥反应状态的变化更多是由于其活性或数量的调节不同,而非移植器官中克隆群体的改变。鉴于在介导排斥反应的T淋巴细胞中,受控动物模型会产生可预测的BV使用情况,了解与人类排斥反应相关的TCR基因使用的决定因素可能会应用于特异性靶向免疫治疗。